61 results
8-K
EX-99.1
MYMD
MyMD Pharmaceuticals Inc
4 Oct 23
MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023
4:30pm
risk of hospitalization, disability, and death.
MyMD also recently announced that the U.S. Food and Drug Administration (FDA) has accepted
8-K
EX-99.1
0yq7bv
14 Aug 23
Regulation FD Disclosure
8:30am
8-K
EX-99.1
8zi1 i72y0
3 Aug 23
MyMD Pharmaceuticals Phase 2 Trial Update
4:30pm
8-K
EX-99.1
nksseae9v8v
31 Jul 23
MyMD Pharmaceuticals Reports Statistically Significant Positive Topline
9:00am
8-K
EX-99.1
ph6 wi06639mmar6ay1
3 Aug 22
Regulation FD Disclosure
4:30pm
8-K
EX-99.1
y188x1su
26 Jul 22
Regulation FD Disclosure
4:30pm
8-K
EX-99.1
ohecc6jsb1ht8
5 Jan 22
MyMD Pharmaceuticals Announces Issuance of New U.S. Patent Covering MYMD-1 in a Method of Treating Sarcopenia
9:28am